Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433532 | 0.81 | NR1H2 (0.35) | KIF11CYP11B2 | |
| SCHEMBL2426847 | 0.80 | CYP11B2 (0.43) | HSD17B1HSD17B2CYP11B2PDE3BPDE3A | |
| SCHEMBL9586460 | 0.80 | APP (0.42) | HSD17B1HSD17B2 | |
| SCHEMBL7569150 | 0.80 | S1PR1 (0.38) | — | |
| SCHEMBL6513958 | 0.79 | ACHE (0.35) | — | |
| SCHEMBL2013844 | 0.79 | CYP11B2 (0.33) | CYP11B2 | |
| SCHEMBL8636681 | 0.79 | HSD11B1 (0.45) | HSD17B1HSD17B2CYP11B2TRPA1CYP11B1 | |
| SCHEMBL3829054 | 0.77 | KIF11 (0.45) | KIF11 | |
| SCHEMBL1369135 | 0.77 | KIF11 (0.39) | KIF11CYP11B2 | |
| SCHEMBL8323540 | 0.77 | NOTUM (0.40) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013182433-A1 | A PROCESS USING GRIGNARD REAGENTS | BASF SE (DE) | 2013-12-12 | — | — | WO | disclosed |
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | disclosed |
| EP-2547687-A1 | A PROCESS USING GRIGNARD REAGENTS | BASF SE (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | US | disclosed |
| EP-2513067-A1 | METHOD FOR PRODUCING TRIAZOLINTHIONE DERIVATIVES AND INTERMEDIATES THEREOF | BASF SE (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| WO-2011113820-A1 | A PROCESS USING GRIGNARD REAGENTS | BASF SE (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, GOT2 | KIF11 4327/4885SLC22A12 2587/4885HSD17B1 581/4885 |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PYGL | KIF11 4336/4885SLC22A12 2753/4885HSD17B1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.